Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EI-1071 Food Effect Study in Healthy Volunteers
NCT07903337Phase 1Not yet recruiting
- Sponsor
- Elixiron Immunotherapeutics
- Start
- Nov 2026
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial of enrupatinib (3 arms), sponsored by Elixiron Immunotherapeutics. Primary endpoints: Area under the curve from time 0 to the last quantifiable time, Area under the curve from time 0 to infinity and 10 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
enrupatinib
Beyond the preview
Go deeper on NCT07903337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07903337.